Pub Date : 2019-01-02DOI: 10.32474/OJNBD.2019.02.000134
M. Jedynak, Marta Sudoł Malisz, A. Brodziak, A. Różyk-Myrta
The processes of ageing and the related impairment of maintaining homeostasis, understood as the loss of adaptive abilities, lead to an increased susceptibility to developing delirium among the elderly. The pathophysiological process of delirium development is dependent on the presence of causative and predisposing factors; for example, neurotransmission process disorders (cholinergic, serotonin and dopaminergic regulation), resulting in metabolic inefficiency of the brain. The symptoms of delirium differ in duration and severity; there are 3 clinical subtypes of delirium: hypoactive, hyperactive and mixed. Moreover, subsequent evaluations using methodological tools have made it possible to distinguish an additional subtype of delirium the no-motor subtype. Recognizing the delirium subtype is essential it identifies high-risk patients, has an effect on the procedures, treatment and further prognosis. Medical personnel working with elderly patients ought to be well familiar with the predisposing factors, non-pharmacological procedures, treatment and prognosis of delirium; they also are required to know how to differentiate between each delirium subtype. Physicians should be aware that the hypoactive subtype of delirium indicates a much worse prognosis for patients.
{"title":"Etiological and Symptomatological Differences Between Hyperactive and Hypoactive Delirium Subtypes","authors":"M. Jedynak, Marta Sudoł Malisz, A. Brodziak, A. Różyk-Myrta","doi":"10.32474/OJNBD.2019.02.000134","DOIUrl":"https://doi.org/10.32474/OJNBD.2019.02.000134","url":null,"abstract":"The processes of ageing and the related impairment of maintaining homeostasis, understood as the loss of adaptive abilities, lead to an increased susceptibility to developing delirium among the elderly. The pathophysiological process of delirium development is dependent on the presence of causative and predisposing factors; for example, neurotransmission process disorders (cholinergic, serotonin and dopaminergic regulation), resulting in metabolic inefficiency of the brain. The symptoms of delirium differ in duration and severity; there are 3 clinical subtypes of delirium: hypoactive, hyperactive and mixed. Moreover, subsequent evaluations using methodological tools have made it possible to distinguish an additional subtype of delirium the no-motor subtype. Recognizing the delirium subtype is essential it identifies high-risk patients, has an effect on the procedures, treatment and further prognosis. Medical personnel working with elderly patients ought to be well familiar with the predisposing factors, non-pharmacological procedures, treatment and prognosis of delirium; they also are required to know how to differentiate between each delirium subtype. Physicians should be aware that the hypoactive subtype of delirium indicates a much worse prognosis for patients.","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44943257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-18DOI: 10.32474/ojnbd.2018.02.000133
Woodward Kiel, Wright Rhonda, Rathore Geetanjali
Menstrual psychosis is a rare disorder that causes psychotic symptoms in conjunction with a patient’s menstrual cycle. We present a case of a 14-year-old girl who presents with such symptoms. Our patient presented with five days of somnolence, paranoia, and visual hallucinations soon after a diagnosis of streptococcal pharyngitis and being started on antimicrobial therapy. Her neurologic exam was significant for flat affect and psychomotor slowing. A thorough work-up consisting of brain MRI, EEG, LP, encephalopathy panel, along with metabolic, infectious, and inflammatory laboratory analysis was unremarkable, and she recovered without therapy about one week after symptom onset. Patient had recurrence and spontaneous resolution of her symptoms two more times over the next 10 months with repeat work-up negative; her family noted that the onset of her symptoms always seemed to coincide with the onset of her menses. She was started on combination oral contraceptive pills and has had no further recurrence of her symptoms since then.
{"title":"A Case of Menstrual Psychosis, an Under Recognized Diagnosis","authors":"Woodward Kiel, Wright Rhonda, Rathore Geetanjali","doi":"10.32474/ojnbd.2018.02.000133","DOIUrl":"https://doi.org/10.32474/ojnbd.2018.02.000133","url":null,"abstract":"Menstrual psychosis is a rare disorder that causes psychotic symptoms in conjunction with a patient’s menstrual cycle. We present a case of a 14-year-old girl who presents with such symptoms. Our patient presented with five days of somnolence, paranoia, and visual hallucinations soon after a diagnosis of streptococcal pharyngitis and being started on antimicrobial therapy. Her neurologic exam was significant for flat affect and psychomotor slowing. A thorough work-up consisting of brain MRI, EEG, LP, encephalopathy panel, along with metabolic, infectious, and inflammatory laboratory analysis was unremarkable, and she recovered without therapy about one week after symptom onset. Patient had recurrence and spontaneous resolution of her symptoms two more times over the next 10 months with repeat work-up negative; her family noted that the onset of her symptoms always seemed to coincide with the onset of her menses. She was started on combination oral contraceptive pills and has had no further recurrence of her symptoms since then.","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49632806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-08DOI: 10.32474/OJNBD.2018.02.000129
S. Bouomrani, Nesrine Regaïeg
Introduction: Kikuchi-Fujimoto’s disease (KFD) or histiocytic necrotizing lymphadenitis is a rare entity that may represent a real diagnostic challenge for the clinician because of its highly polymorphous and sometimes unusual presentations. We report an original observation of KFD with aseptic meningitis as inaugural manifestation. Case report: 30-year-old woman, without pathological medical history, was hospitalized via the emergency department for exploration of a meningeal syndrome with cervical lymphadenopathies. The lumbar puncture showed aseptic meningitis: clear, normotensive cerebrospinal fluid with leukocytes at 28/mm3 (90% lymphocytes), red blood cells at 2/mm3, proteinrrhachia at 0.58 g/l, glucorrachia at 4 mmol/l for venous glycemia at 8 mmol/l, and negative direct examination and culture. Cerebromedullary MRI and cerebral angio-MR were without abnormalities. Further infectious and immunological investigations were negative. Cervical lymph node biopsy showed histological and Immunohistochemical aspects suggesting KFD. Treated with systemic corticosteroids, the evolution was favorable with no recurrence. Conclusion: KFD-associated aseptic meningitis remains rare, and the inaugural forms are exceptional and often difficult to diagnose. A better knowledge of this association avoids unnecessary investigations, recurrence, and improves the prognosis of the disease.
{"title":"Aseptic meningitis revealing isolated Kikuchi-Fujimoto disease","authors":"S. Bouomrani, Nesrine Regaïeg","doi":"10.32474/OJNBD.2018.02.000129","DOIUrl":"https://doi.org/10.32474/OJNBD.2018.02.000129","url":null,"abstract":"Introduction: Kikuchi-Fujimoto’s disease (KFD) or histiocytic necrotizing lymphadenitis is a rare entity that may represent a real diagnostic challenge for the clinician because of its highly polymorphous and sometimes unusual presentations. We report an original observation of KFD with aseptic meningitis as inaugural manifestation. Case report: 30-year-old woman, without pathological medical history, was hospitalized via the emergency department for exploration of a meningeal syndrome with cervical lymphadenopathies. The lumbar puncture showed aseptic meningitis: clear, normotensive cerebrospinal fluid with leukocytes at 28/mm3 (90% lymphocytes), red blood cells at 2/mm3, proteinrrhachia at 0.58 g/l, glucorrachia at 4 mmol/l for venous glycemia at 8 mmol/l, and negative direct examination and culture. Cerebromedullary MRI and cerebral angio-MR were without abnormalities. Further infectious and immunological investigations were negative. Cervical lymph node biopsy showed histological and Immunohistochemical aspects suggesting KFD. Treated with systemic corticosteroids, the evolution was favorable with no recurrence. Conclusion: KFD-associated aseptic meningitis remains rare, and the inaugural forms are exceptional and often difficult to diagnose. A better knowledge of this association avoids unnecessary investigations, recurrence, and improves the prognosis of the disease.","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47662914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-22DOI: 10.32474/OJNBD.2018.02.000128
A. K. Roy, Saurabh Sadekar, R. Maloo, S. Murali
{"title":"Rituximab-Rescue Therapy in Autoimmune Neurological Disorders","authors":"A. K. Roy, Saurabh Sadekar, R. Maloo, S. Murali","doi":"10.32474/OJNBD.2018.02.000128","DOIUrl":"https://doi.org/10.32474/OJNBD.2018.02.000128","url":null,"abstract":"","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41379116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-28DOI: 10.32474/OJNBD.2018.02.000127
Aliyev Na, Z. Aliyev
{"title":"A Double-Blind Placebo-Controlled Trial of Acediprol (Valproate Sodium) For Global Severity in Child Autism Spectrum Disorders","authors":"Aliyev Na, Z. Aliyev","doi":"10.32474/OJNBD.2018.02.000127","DOIUrl":"https://doi.org/10.32474/OJNBD.2018.02.000127","url":null,"abstract":"","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47100951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-20DOI: 10.32474/ojnbd.2018.01.000125
Ronaldo Chicre Araujo
{"title":"Neurosis and Psychosis in German and French Nosography","authors":"Ronaldo Chicre Araujo","doi":"10.32474/ojnbd.2018.01.000125","DOIUrl":"https://doi.org/10.32474/ojnbd.2018.01.000125","url":null,"abstract":"","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69690403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-05DOI: 10.32474/OJNBD.2018.01.000123
Lisa Marie Portugal
The PEN-3 Model Cultural Framework can be used to design culturally specific, locally relevant health intervention and prevention programs to educate communities. This health intervention and prevention involves educating Hispanic females and males between the ages of 15 to 32. The health and wellness program design involve educating this group about the use of marijuana and its damaging effects on the body leading to mental illness, Diabetes, Cancer, lung and other organ damage, obesity, cognitive disorders, lowered IQ and EQ (emotional quotient), and various other damaging effects. Finally, a summary of the PEN-3 Model Cultural findings are discussed and analyzed to help health educators, practitioners, and advocates serve and address the needs of the target population.
{"title":"Running head: PEN-3 Model Cultural Framework for Health Intervention and Prevention","authors":"Lisa Marie Portugal","doi":"10.32474/OJNBD.2018.01.000123","DOIUrl":"https://doi.org/10.32474/OJNBD.2018.01.000123","url":null,"abstract":"The PEN-3 Model Cultural Framework can be used to design culturally specific, locally relevant health intervention and prevention programs to educate communities. This health intervention and prevention involves educating Hispanic females and males between the ages of 15 to 32. The health and wellness program design involve educating this group about the use of marijuana and its damaging effects on the body leading to mental illness, Diabetes, Cancer, lung and other organ damage, obesity, cognitive disorders, lowered IQ and EQ (emotional quotient), and various other damaging effects. Finally, a summary of the PEN-3 Model Cultural findings are discussed and analyzed to help health educators, practitioners, and advocates serve and address the needs of the target population.","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47535768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-08-29DOI: 10.32474/OJNBD.2018.01.000122
J. Bossu
The sodium valproate (VPA) is a very simple structural compound derived from the valeric acid produced by a plant “Valeriana officinalis†. Extract s of this this plant were used by the doctors of Ancient Greece to cure insomnia and by the Romans to treat palpitations and arrhythmia. VPA was used for the first time as an anticonvulsant in 1963 [1] and in 1974 Jevson and Clark [2] after their clinical study on 63 patients whom 40 of them had failed to respond to other anticonvulsants concluded that in 43% of patients, epilepsy stopped completely, and in 22% of patients, the attacks were reduced by 50%. An unusual side effect was temporary hair loss. Since then VPA is widely used to treat almost all types of seizures and epilepsy syndromes, and is used successfully, for patients displaying epilepsy resistant to other medications [3]. Behind its anticonvulsants effect, VPA targets also a wide range of neurological diseases including some neurodegenerative pathologies, addiction, bipolar and obsessive-compulsive disorders and migraine [4].
{"title":"The Sodium Valproate: Doctor Jekyll and Mister Hyde","authors":"J. Bossu","doi":"10.32474/OJNBD.2018.01.000122","DOIUrl":"https://doi.org/10.32474/OJNBD.2018.01.000122","url":null,"abstract":"The sodium valproate (VPA) is a very simple structural compound derived from the valeric acid produced by a plant “Valeriana officinalis†. Extract s of this this plant were used by the doctors of Ancient Greece to cure insomnia and by the Romans to treat palpitations and arrhythmia. VPA was used for the first time as an anticonvulsant in 1963 [1] and in 1974 Jevson and Clark [2] after their clinical study on 63 patients whom 40 of them had failed to respond to other anticonvulsants concluded that in 43% of patients, epilepsy stopped completely, and in 22% of patients, the attacks were reduced by 50%. An unusual side effect was temporary hair loss. Since then VPA is widely used to treat almost all types of seizures and epilepsy syndromes, and is used successfully, for patients displaying epilepsy resistant to other medications [3]. Behind its anticonvulsants effect, VPA targets also a wide range of neurological diseases including some neurodegenerative pathologies, addiction, bipolar and obsessive-compulsive disorders and migraine [4].","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43562316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-07-25DOI: 10.32474/OJNBD.2018.01.000120
Y. Yazğan
Is currently used as a comprehensive definition covering “brain disorders”, neurological diseases and mental disorders. While schizophrenia, depression, panic disorder, drug addiction and insomnia are referred to as “mental disorders”, Epilepsy, Alzheimer, Parkinson, Huntington’s disease (HD) and multiple sclerosis are considered as “neurological disorders”. Current therapies of these very common diseases require continuous drug use and at the same time cause many different side effects. Therefore preclinical and clinical investigations for new treatment approaches are on the rise. Especially the identification of the molecular basis of these diseases is the focus of researches. Examination of transient receptor potential (TRP) channels is at an early stage in the investigation of the molecular principle of these diseases, but clear results regarding the efficacy of substances activating or inhibiting these channels have not been obtained. Some diseases have been based on mutations of TRP channels. However, only a few TRP channelopathies, have been conclusively identified so far [1]. Investigation of TRP channels in psychiatric disorders will contribute to a better understanding of the etiology of psychiatric disorders and the development of new pharmacological treatments. Abbreviations: TRP: Transient Receptor Potential; GPCR: G Protein Coupled Receptor; TRPV1: TRP Vanilloid 1; CGRP: Calcitonin Gene Related Peptide; CNS: Central Nervous System; SOC: Store Operated Calcium Channels; BDNF: Brain Derived Neurotrophic Factor; Mwk: Moon Walker Mouse; BD-I: Bipolar Disorder Type I; ALS-G: Guamanian Amyotrophic Lateral Sclerosis ISSN: 2637-6628 DOI: 10.32474/OJNBD.2018.01.000120 On J Neur & Br Disord Copyrights@ Yener Yazğan. Citation: Yener Y, Betül Y. Neurological Diseases and Relation of TRP Channels. On J Neur & Br Disord 1(4)2018. OJNBD. MS.ID.000120. DOI: 10.32474/OJNBD.2018.01.000120. 71 TRP Channels in Brain Disorders TRPV1 and TRPA1 Significant evidence has been obtained that TRPV1 antagonists have anxiolytic activity in preclinical studies, but the antidepressant effect is not clear [6]. There is no direct evidence that TRP channels play a role in schizophrenia. However, the fact that TRPV1 channels play a role in central dopaminergic and cannabinoid mechanisms may suggests the potential role of these channels in schizophrenia [5]. CGRP release from trigeminal vasculature neuron network and neurogenic inflammatory response are currently accepted mechanisms for migraine attack pathophysiology. In particular, the TRP vanilloid 1 (TRPV1) and the TRP ankyrin 1 (TRPA1) are expressed in nociceptive neurons, which also express the sensory neuropeptides, tachykinins, and calcitonin gene-related peptide (CGRP), which mediate neurogenic inflammatory responses. This evidence suggests that these channels may be an important therapeutic goal in migraine treatment [7].
{"title":"Neurological Diseases and Relation of TRP Channels","authors":"Y. Yazğan","doi":"10.32474/OJNBD.2018.01.000120","DOIUrl":"https://doi.org/10.32474/OJNBD.2018.01.000120","url":null,"abstract":"Is currently used as a comprehensive definition covering “brain disorders”, neurological diseases and mental disorders. While schizophrenia, depression, panic disorder, drug addiction and insomnia are referred to as “mental disorders”, Epilepsy, Alzheimer, Parkinson, Huntington’s disease (HD) and multiple sclerosis are considered as “neurological disorders”. Current therapies of these very common diseases require continuous drug use and at the same time cause many different side effects. Therefore preclinical and clinical investigations for new treatment approaches are on the rise. Especially the identification of the molecular basis of these diseases is the focus of researches. Examination of transient receptor potential (TRP) channels is at an early stage in the investigation of the molecular principle of these diseases, but clear results regarding the efficacy of substances activating or inhibiting these channels have not been obtained. Some diseases have been based on mutations of TRP channels. However, only a few TRP channelopathies, have been conclusively identified so far [1]. Investigation of TRP channels in psychiatric disorders will contribute to a better understanding of the etiology of psychiatric disorders and the development of new pharmacological treatments. Abbreviations: TRP: Transient Receptor Potential; GPCR: G Protein Coupled Receptor; TRPV1: TRP Vanilloid 1; CGRP: Calcitonin Gene Related Peptide; CNS: Central Nervous System; SOC: Store Operated Calcium Channels; BDNF: Brain Derived Neurotrophic Factor; Mwk: Moon Walker Mouse; BD-I: Bipolar Disorder Type I; ALS-G: Guamanian Amyotrophic Lateral Sclerosis ISSN: 2637-6628 DOI: 10.32474/OJNBD.2018.01.000120 On J Neur & Br Disord Copyrights@ Yener Yazğan. Citation: Yener Y, Betül Y. Neurological Diseases and Relation of TRP Channels. On J Neur & Br Disord 1(4)2018. OJNBD. MS.ID.000120. DOI: 10.32474/OJNBD.2018.01.000120. 71 TRP Channels in Brain Disorders TRPV1 and TRPA1 Significant evidence has been obtained that TRPV1 antagonists have anxiolytic activity in preclinical studies, but the antidepressant effect is not clear [6]. There is no direct evidence that TRP channels play a role in schizophrenia. However, the fact that TRPV1 channels play a role in central dopaminergic and cannabinoid mechanisms may suggests the potential role of these channels in schizophrenia [5]. CGRP release from trigeminal vasculature neuron network and neurogenic inflammatory response are currently accepted mechanisms for migraine attack pathophysiology. In particular, the TRP vanilloid 1 (TRPV1) and the TRP ankyrin 1 (TRPA1) are expressed in nociceptive neurons, which also express the sensory neuropeptides, tachykinins, and calcitonin gene-related peptide (CGRP), which mediate neurogenic inflammatory responses. This evidence suggests that these channels may be an important therapeutic goal in migraine treatment [7].","PeriodicalId":93346,"journal":{"name":"Online journal of neurology and brain disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41645613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：